These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 21715171)
1. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. Chang CN; Huang YC; Yang DM; Kikuta K; Wei KJ; Kubota T; Yang WK J Clin Neurosci; 2011 Aug; 18(8):1048-54. PubMed ID: 21715171 [TBL] [Abstract][Full Text] [Related]
2. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471 [TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Yamanaka R; Homma J; Yajima N; Tsuchiya N; Sano M; Kobayashi T; Yoshida S; Abe T; Narita M; Takahashi M; Tanaka R Clin Cancer Res; 2005 Jun; 11(11):4160-7. PubMed ID: 15930352 [TBL] [Abstract][Full Text] [Related]
4. T cell adoptive immunotherapy of newly diagnosed gliomas. Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070 [TBL] [Abstract][Full Text] [Related]
5. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. De Vleeschouwer S; Fieuws S; Rutkowski S; Van Calenbergh F; Van Loon J; Goffin J; Sciot R; Wilms G; Demaerel P; Warmuth-Metz M; Soerensen N; Wolff JE; Wagner S; Kaempgen E; Van Gool SW Clin Cancer Res; 2008 May; 14(10):3098-104. PubMed ID: 18483377 [TBL] [Abstract][Full Text] [Related]
6. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Liau LM; Prins RM; Kiertscher SM; Odesa SK; Kremen TJ; Giovannone AJ; Lin JW; Chute DJ; Mischel PS; Cloughesy TF; Roth MD Clin Cancer Res; 2005 Aug; 11(15):5515-25. PubMed ID: 16061868 [TBL] [Abstract][Full Text] [Related]
7. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Yu JS; Wheeler CJ; Zeltzer PM; Ying H; Finger DN; Lee PK; Yong WH; Incardona F; Thompson RC; Riedinger MS; Zhang W; Prins RM; Black KL Cancer Res; 2001 Feb; 61(3):842-7. PubMed ID: 11221866 [TBL] [Abstract][Full Text] [Related]
9. Dendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects: clinical trial protocol. Shah AH; Bregy A; Heros DO; Komotar RJ; Goldberg J Neurosurgery; 2013 Nov; 73(5):863-7. PubMed ID: 23867302 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465 [TBL] [Abstract][Full Text] [Related]
11. Cell- and peptide-based immunotherapeutic approaches for glioma. Yamanaka R Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264 [TBL] [Abstract][Full Text] [Related]
12. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Wheeler CJ; Black KL; Liu G; Mazer M; Zhang XX; Pepkowitz S; Goldfinger D; Ng H; Irvin D; Yu JS Cancer Res; 2008 Jul; 68(14):5955-64. PubMed ID: 18632651 [TBL] [Abstract][Full Text] [Related]
13. Autologous natural killer cell therapy for human recurrent malignant glioma. Ishikawa E; Tsuboi K; Saijo K; Harada H; Takano S; Nose T; Ohno T Anticancer Res; 2004; 24(3b):1861-71. PubMed ID: 15274367 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. Cho DY; Yang WK; Lee HC; Hsu DM; Lin HL; Lin SZ; Chen CC; Harn HJ; Liu CL; Lee WY; Ho LH World Neurosurg; 2012; 77(5-6):736-44. PubMed ID: 22120301 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas. Katano M; Morisaki T; Koga K; Nakamura M; Onishi H; Matsumoto K; Tasaki A; Nakashima H; Akiyoshi T; Nakamura M Anticancer Res; 2005; 25(6A):3771-6. PubMed ID: 16302738 [TBL] [Abstract][Full Text] [Related]
16. [Dendritic cell therapy for malignant glioma]. Yamanaka R; Homma J; Yajima N; Tsuchiya N; Tanaka R No To Shinkei; 2003 Sep; 55(9):771-80. PubMed ID: 14571839 [TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692 [TBL] [Abstract][Full Text] [Related]
18. Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma. Jie X; Hua L; Jiang W; Feng F; Feng G; Hua Z Cell Biochem Biophys; 2012 Jan; 62(1):91-9. PubMed ID: 21909820 [TBL] [Abstract][Full Text] [Related]
19. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY Front Immunol; 2018; 9():727. PubMed ID: 29910795 [TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy of CNS malignancies. Plautz GE; Shu S Cancer Chemother Biol Response Modif; 2001; 19():327-38. PubMed ID: 11686021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]